Virtu KCG Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Virtu KCG Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$3.24M	Buy	26,640 +22,845	+602%	+$2.66M	0.09%	120
2017 Q1	$460K	Buy	+3,795	New	+$489K	0.01%	1476
2016 Q4	–	Sell	-28,076	Closed	-$3.44M	–	3948
2016 Q3	$3.44M	Buy	28,076 +18,302	+187%	+$2.36M	0.08%	146
2016 Q2	$1.14M	Buy	9,774 +4,127	+73%	+$586K	0.02%	658
2016 Q1	$786K	Sell	5,647 -697	-11%	-$102K	0.02%	766
2015 Q4	$1.21M	Buy	+6,344	New	+$1.11M	0.02%	701
2015 Q3	–	Sell	-1,398	Closed	-$253K	–	3984
2015 Q2	$253K	Sell	1,398 -13,183	-90%	-$2.28M	﹤0.01%	2294
2015 Q1	$2.53M	Buy	14,581 +9,037	+163%	+$1.64M	0.05%	289
2014 Q4	$1.03M	Buy	5,544 +3,284	+145%	+$609K	0.02%	917
2014 Q3	$375K	Sell	2,260 -8,420	-79%	-$1.38M	0.01%	2045
2014 Q2	$1.67M	Buy	+10,680	New	+$1.69M	0.03%	665
2014 Q1	–	Sell	-2,439	Closed	-$324K	–	4255
2013 Q4	$324K	Sell	2,439 -7,314	-75%	-$878K	﹤0.01%	2487
2013 Q3	$1.13M	Buy	+9,753	New	+$1.07M	0.01%	1057

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtu KCG Holdings's ALXN Position: Q2 2017 in Review

Virtu KCG Holdings increased its Alexion Pharmaceuticals (ALXN) stake by 602% in Q2 2017, buying an estimated $2.66M and bringing the position to 26,640 shares worth $3.24M. The position accounts for 0.09% of the portfolio, ranked #120.

Virtu KCG Holdings first reported a position in ALXN in Q3 2013 and has held it in 13 quarters since. The position peaked at $3.44M in Q3 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Virtu KCG Holdings held 26,640 shares of Alexion Pharmaceuticals worth $3.24M as of Q2 2017.
Virtu KCG Holdings bought 22,845 Alexion Pharmaceuticals shares in Q2 2017, an estimated $2.66M.
Alexion Pharmaceuticals made up 0.09% of Virtu KCG Holdings's portfolio in Q2 2017, its #120 holding.
Virtu KCG Holdings first reported a position in Alexion Pharmaceuticals in Q3 2013 and has held it in 13 quarters since.
Virtu KCG Holdings's Alexion Pharmaceuticals position peaked at $3.44M in Q3 2016.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.